Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
Current Price
$0.24
+16.93%Jupiter Neurosciences Inc (JUNS) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Jupiter Neurosciences Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $40448.00. Gross profit (TTM) is $31855.00. EBITDA is $-8.99M. Earnings per share (EPS) is $-0.25. The P/E ratio is -0.77. Market capitalization is $7.06M.
Free cash flow (FCF) is $-5.41M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Jupiter Neurosciences Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
